摘要
Abstract
Objective To observe the clinical efficacy of dexamethasone intravitreal implant(Ozurdex)in the treatment of diabetic macular edema(DME).Methods This was a retrospective clinical study,we selected 14 cases(15 eyes)with Ozurdex because of DME in Tianjin bright eye hospital from January 2022 to January 2023.The patients were followed up at 1 week,1 month,2 months,3 months,4 months,5 months and 6 months after operation to observe the best corrected visual acuity(BCVA),central retinal thickness(CMT),intraocular pressure(IOP)and the state of Ozurdex.Results The BCVA at each time point after treatment was higher than that before treatment(F=6.93,P<0.05),the CMT at 1 week[(425.80±96.86)μm],1 month[(313.33±76.88)μm],2 months[(266.07±75.27)μm],3 months[(279.93±55.68)μm],4 months[(327.13±105.67)μm],5 months[(298.73±61.89)μm]and 6 months[(321.00±98.41)μm]after operation were significantly lower than that before treatment[(575.00±136.82)μm](F=18.91,P<0.05).With the decrease of CMT after treatment,the intraretinal cysts,hyperreflective dots and subretinal fluid were gradually absorbed,the external limiting membrane and ellipsoid zone were also partially recovered.The intraocular pressure was significantly higher within 5 months after treatment than that before treatment(P<0.05),but did not change significantly at 6 months compared with before treatment(P>0.05).Conclusion Ozurdex can effectively reduce macular edema,restore retinal morphology and interlaminar structure,improve BCVA in the treatment of DME.关键词
地塞米松/黄斑水肿/糖尿病视网膜病变Key words
Dexamethasone/Macular edema/Diabetic retinopathy分类
医药卫生
